NEW YORK, April 12, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that the Company has added new members to its executive management group. Mr. Robert J. Sexauer has joined the Company as its Executive Vice President. Mr. Sexauer, a 30 year medical technology and regenerative medicine specialist, will concentrate on planned clinical studies as well as corporate development functions. The Company has also announced that Sarah R. Young has joined the Company as Director of Quality Assurance. Ms. Young has over 10 years of experience developing and implementing quality systems pertaining to the field of tissue processing and tissue banking.
Mr. Sexauer noted, "I am very pleased to be part of a talented management team focused on autologous (your own) cellular therapies. IntelliCell has the remarkable potential to be a leader in the field of regenerative medicine."
Added Ms. Young, "The IntelliCell process for developing cell therapy solutions is very exciting and our group will focus on implementing the highest quality standards for the industry and all of our stakeholders."
Dr. Steven Victor, Chairman and CEO of IntelliCell BioSciences stated that, "We are committed to building a Company poised to achieve sustained growth over the long term. We believe our people, our process, and our products are well positioned to make a positive impact on the practice of better medicine. IntelliCell is pleased to have Mr. Sexauer and Ms. Young join our team as we continue to pioneer new medical treatments using our proprietary cellular products."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (HCT/P's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to enter into technology licensing agreements that cover a particular international territory or country.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: [email protected]
SOURCE IntelliCell BioSciences, Inc.